Patient description: The patient is a 16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities. She had a positive anti-AChR antibody test, and her single fiber electromyography (SFEMG) was positive. She is on acetylcholinesterase inhibitor treatment combined with immunosuppressants. But she still has some symptoms. She does not smoke or use illicit drugs. She is not sexually active, and her menses are regular. Her physical exam and lab studies are not remarkable for any other abnormalities. BP: 110/75 Hgb: 11 g/dl WBC: 8000 /mm3 Plt: 300000 /ml Creatinine: 0.5 mg/dl BUN: 10 mg/dl Beta hcg: negative for pregnancy

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Acute Myeloblastic Leukemia For intensive chemotherapy: 1. Patients with the novo AML or secondary to MDS or previous treatment, regardless of age. 2. Signed written informed consent. 3. ECOG ≤ 2. If ECOG is greater than 2 due to AML, the patient can be included in the study. 4. LVEF > 40 % measured by means of echocardiography. 5. If background of respiratory disease (not related to the AML), risk factors or clinical for COPD, the values of functional tests, including DLCO, should be greater than 50% of the expected. 6. Bilirubin, alkaline phosphatase and ALT < of 3 fold the upper normal value, providing that it is not due to the disease that motivates the treatment (AML). 7. Serum creatinine < 2,5 mg/dL providing that it is not due to the disease that motivates the treatment (AML). 8. In fertile aged women, negative pregnancy test and use of contraception methods are required. Any patient who does not meet the and  for treatment with intensive chemotherapy can be evaluated individually when considering that could still obtain benefit from this treatment considering that could still obtain benefit from this treatment. for GO administration in patient candidates for intensive chemotherapy Same for intensive chemotherapy, including the following specifications: 1. CD33 positive (more than 5 % of the leukemic population) 2. for treatment with GO in cases of serious hepatic disease not due to AML. 3. In patients who are going to receive GO in two cycles, the second one will be only administrated if the toxicity due to the first cycle is recovered. 4. Though the GO administered dose is much lower than usual, it is recommended a period of two months between GO administration and hematopoietic stem cell transplantation (HSCT). for the modification of high dose ARA-C The dose of Ara-C in cycles containing HiDAC should be reduced in the following cases: 1. The hematopoietic recovery in the previous cycle has been longer than 28 days. 2. Presence in the previous cycles of a confluent maculopapular rash or drug-induced shedding. 3. More than 4 episodes of watery diarrhea per day. 4. Increase of 4 fold the previous normal value of aminotransferases or alkaline phosphatase in any of the cycles. 5. Total bilirubin greater than 3 mg/dL in any of the cycles. 6. Treatment with HiDAC will be definitively suspended (even that included in the BEA conditioning) when previous toxicity severe cerebellar ataxia, confusion or another sign of central nervous toxicity that has not another clear explanation Patients with blastic crisis of a chronic myeloid leukemia or other myeloproliferative syndromes evolving to acute leukemia. 2. Patients with AML in relapse. 3. Acute promyelocytic leukemia (M3 or M3v). 4. Absence of signed written informed consent. 5. ECOG ≥ 3 that it is not due to the disease that motivates the treatment (AML). 6. LVEF < 40 % determined by echocardiography study. 7. Values of respiratory functional tests, including DLCO, lower than 50% of the expected. 8. Bilirubin, alkaline phosphatase or GOT > 3 fold the upper normal value, providing that it is not due to the disease that motivates the treatment (AML). 9. Serum creatinine > of 2.5 mg/dL providing that it is not due to the disease that motivates the treatment (AML). 10. Positive pregnancy test or not use of effective contraception in fertile aged women. 11. Previous treatment with antileukemic chemotherapy, except hydroxyurea. 12. Presence of an active neoplasia different from the AML. 13. Presence of a serious psychiatric disease. 14. Positive HIV test. 15. Any other condition which limits or dissuades from the treatment with intensive chemotherapy, especially with anthracyclines